-
公开(公告)号：WO2009149189A3
公开(公告)日：2010-03-04
申请号：PCT/US2009046137
申请日：2009-06-03
Applicant: ABBOTT LAB , GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , WU CHENGBIN , HUGUNIN MARGARET , KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH J
Inventor： GHAYUR TARIQ , ISAKSON PETER C , OLSON LISA M , WU CHENGBIN , HUGUNIN MARGARET , KAMATH RAJESH V , CUFF CAROLYN A , ALLEN HAMISH J
CPC classification number: C07K16/2887 , A61K39/3955 , A61K45/06 , A61K47/48546 , A61K47/6845 , A61K2039/505 , A61K2039/70 , C07K16/22 , C07K16/241 , C07K16/244 , C07K16/245 , C07K16/247 , C07K16/248 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/64 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/545
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，具体涉及用于预防，诊断和/或治疗疾病的用途。
-
Patent Agency Ranking
公开(公告)号：WO2014113804A9
公开(公告)日：2014-07-24
申请号：PCT/US2014/012364
申请日：2014-01-21
Applicant: ABBVIE INC. , VOSS, Jeffrey, W. , CUFF, Carolyn, A.
Inventor： VOSS, Jeffrey, W. , CUFF, Carolyn, A.
Abstract: The invention provides methods for predicting the efficacy of anti-TNF and anti- IL17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level CXCL1 and/or CXCL5 markers in a sample derived from the subject.
-
3.发明申请ANTI-TNF AND ANTI-IL17 COMBINATION THERAPY BIOMARKERS FOR INFLAMMATORY DISEASE 审中-公开抗TNF和抗IL17联合治疗炎症性疾病的生物标志物
公开(公告)号：WO2014113804A1
公开(公告)日：2014-07-24
申请号：PCT/US2014012364
申请日：2014-01-21
Applicant: ABBVIE INC , VOSS JEFFREY W , CUFF CAROLYN A
Inventor： VOSS JEFFREY W , CUFF CAROLYN A
CPC classification number: G01N33/6863 , A61K39/3955 , C12Q1/6883 , G01N2333/522 , G01N2333/525 , G01N2333/54 , G01N2800/52
Abstract: The invention provides methods for predicting the efficacy of anti-TNF and anti- IL17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level CXCL1 and/or CXCL5 markers in a sample derived from the subject.
Abstract translation: 本发明提供了通过确定源自受试者的样品中的CXCL1和/或CXCL5水平的水平来预测抗TNF和抗IL17联合疗法在治疗患有炎性疾病的受试者中的功效的方法。
-
公开(公告)号：WO2009149189A2
公开(公告)日：2009-12-10
申请号：PCT/US2009/046137
申请日：2009-06-03
Applicant: ABBOTT LABORATORIES , GHAYUR, Tariq , ISAKSON, Peter, C. , OLSON, Lisa, M. , WU, Chengbin , HUGUNIN, Margaret , KAMATH, Rajesh, V. , CUFF, Carolyn, A. , ALLEN, Hamish, J.
Inventor： GHAYUR, Tariq , ISAKSON, Peter, C. , OLSON, Lisa, M. , WU, Chengbin , HUGUNIN, Margaret , KAMATH, Rajesh, V. , CUFF, Carolyn, A. , ALLEN, Hamish, J.
CPC classification number: C07K16/2887 , A61K39/3955 , A61K45/06 , A61K47/6845 , A61K2039/505 , A61K2039/70 , C07K16/22 , C07K16/241 , C07K16/244 , C07K16/245 , C07K16/247 , C07K16/248 , C07K16/2866 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/64 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , G01N33/6869 , G01N2333/545 , Y02A50/386 , Y02A50/41 , Y02A50/412
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，具体涉及用于预防，诊断和/或治疗疾病的用途。
-
公开(公告)号：WO2008127271A3
公开(公告)日：2009-04-09
申请号：PCT/US2007019660
申请日：2007-09-07
Applicant: ABBOTT LAB , WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hTL-13活性有害的病症的人类受试者中。
-
公开(公告)号：WO2008127271A2
公开(公告)日：2008-10-23
申请号：PCT/US2007/019660
申请日：2007-09-07
Applicant: ABBOTT LABORATORIES , WU, Chengbin , DIXON, Richard, W. , BELK, Jonathan, P. , YING, Hua , ARGIRIADI, Maria, A. , CUFF, Carolyn, A. , HINTON, Paul, R. , KUMAR, Shankar , MELIM, Terry, L. , CHEN, Yan
Inventor： WU, Chengbin , DIXON, Richard, W. , BELK, Jonathan, P. , YING, Hua , ARGIRIADI, Maria, A. , CUFF, Carolyn, A. , HINTON, Paul, R. , KUMAR, Shankar , MELIM, Terry, L. , CHEN, Yan
IPC: C07K14/00 , C07K16/00 , C07H21/00 , C12N1/00 , C12N1/21 , C12N5/00 , C12N5/04 , C12N1/15 , C12N5/06 , C12N1/16 , C12P21/00
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y02A50/385 , Y02A50/401 , Y02A50/409 , Y02A50/411 , Y02A50/463 , Y02A50/473 , Y02A50/478 , Y02A50/481
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hTL-13活性有害的病症的人类受试者中。
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
